Ability of systemic lnterleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice

Cancer Research

Volumn 60, Issue 2, 2000, Pages 359-364

  Boggio, Katia ^a   Di Carlo, Emma ^c   Rovero, Stefania ^a   Cavallo, Federica ^a   Quaglino, Elena ^a   Lollini, Pier Luigi ^b   Nanni, Patrizia ^b   Nicoletti, Giordano ^b   Wolf, Stanley ^d   Musiani, Piero ^c   Forni, Guido ^a,e  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d PFIZER INC   (United States)

^e SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GRAFT; CANCER RISK; CARCINOGENESIS; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE; TUMOR CELL; ANIMAL; BAGG ALBINO MOUSE; DISEASE COURSE; EXPERIMENTAL NEOPLASM; GENETICS; MOUSE MAMMARY TUMOR ONCOVIRUS; PATHOLOGY; PROTO ONCOGENE; RAT; TIME; TRANSGENIC MOUSE;

ANIMALS; DISEASE PROGRESSION; FEMALE; GENES, ERBB-2; INTERLEUKIN-12; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); RATS; RECEPTOR, ERBB-2; TIME FACTORS;

EID: 0034649786     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Brunda, M.J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy. M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
2. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schereiber, R. D., and Storkus, W. J. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. I. Immunol., 153: 1697-1706, 1994.
3. Cavallo, F., Signorelli, P., Giovarelli, M., Musiani, P., Modesti, A., Brunda, M. J., Colombo, M. P., and Forni, G. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous 1L-12. J. Natl. Cancer Inst., 89: 1049-1058, 1997.
4. Fujiwara, H., Clark, S. C., and Hamaoka, T. Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Ann, NY Acad. Sci., 795: 294-309, 1996.
5. Trinchieri, G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol., 70: 83-243, 1998.
6. Zilocchi, C., Stoppacciaro, A., Chiodoni, C., Parenza, M., Terrazzini, N., and Colombo, M. P. Interferon γ-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte/macrophage colony-stimulating factor. J. Exp. Med., 188: 133-143, 1998.
7. Cavallo, F., Di Carlo, E., Butera, M., Verrua, R., Colombo, M. P., Musiani, P., and Forni, G. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res., 59: 414-421, 1999.
8. Sgadari, C., Angiolillo, A. L., and Tosato, G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood, 87: 3877-3882, 1996.
9. Ogawa, M., Tsutsui, T., Zou, J. P., Mu, J., Wijesuriya, R., You, W. G., Herrmann, S., Kubo, T., Fujiwara, H., and Hamaoka, T. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin-12. Cancer Res., 57: 2216-2222, 1997.
10. Wigginton, J. M., Kuhns, B. D., Back, T. C., Brunda, M. J., Wiltrout, R. H., and Cox. G. W. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res., 56: 1131-1136, 1996.
11. Tannenbaum, C. S., Wicker, N., Armstrong, D., Tubbs, R., Finke, J., Bukowski, R., and Hamilton, T. A. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12, J. Immunol., 156: 693-699, 1996.
12. Hunter, S. E., Waldburger, K. E., Thibodeaux, D. K., Schaub, R. G., Goldman, S. J., and Leonard, J. P. Immunoregulation by interleukin-12 in MB49.1 tumor bearing mice: cellular and cytokine-mediated effector mechanisms. Eur. J. Immunol., 27: 3438-3446, 1997.
13. Lollini, P. L., Bosco, M. C., Cavallo, F., De Giovanni, C., Giovarelli, M., Landuzzi. L., Musiani, P., Modesti, A., Nicolelti, G., Palmieri, G., Santoni, A., Young, H. A., Forni, G., and Nanni, P. Inhibition of tumor growth and enhancement of metastasis after transfection of the γ-interferon gene. Int. J. Cancer, 55: 320-329, 1993.
14. Coughlin, C. M., Sajhany, K. E., Gee, M. S., LaTemple, D. C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J. E., Farber, J. M., Pestka, S., Trinchieri, G., and Lee, W. M. F. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity, 9: 25-34, 1998.
15. Noguchi, Y., Jungbluth, A., Richards, E. C., and Old, L. J. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl. Acad. Sci. USA, 93: 11798-11801, 1996.
16. Boggio, K., Nicoletti, G., Di Carlo, E., Cavallo, F., Landuzzi, L., Melani, C., Giovarelli, M., Rossi, I., Nanni, P., De Giovanni, C., Bouchard, P., Wolf, S. F., Modesti, A., Musiani, P., Lollini, P. L., Colombo, M. P., and Forni, G. Interleukin-12 mediated prevention of spontaneous mammary adenocarcinomas in two lines of HER2/neu transgenic mice. J. Exp. Med., 188: 589-596, 1998.
17. Lollini, P. L., and Forni, G. Specific and non-specific immunity in the prevention of spontaneous tumors in person at risk. Immunol. Today, 20: 347-350, 1999.
18. Jonsen, R. A., Durfy, S. J., Burke, W., and Motulsky, A. G. The advent of the 'unpatient'. Nat. Med., 2: 622-624, 1996.
19. Sukumar, S., and McKenzie, K. Breast cancer prevention strategies for the twenty-first century. Mol. Med. Today, 2: 453-459, 1996.
20. Lucchini, F., Sacco, M. G., Hu., N., Villa, A., Brown, J., Cesano, L., Mangiarini, L., Rindi, G., Kindl, S., Sessa, F., Vezzoni, P., and Clerici, L. Early and multifocal tumors in breast, salivary, Harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Lett., 64: 203-209, 1992.
21. Guy, C. T., Webster, M. A., Schalle, M., Parsons, T. J., Cardiff, R. D., and Muller, D. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces melastatic disease. Proc. Natl. Acad. Sci. USA. 89: 10578-10582, 1992.
22. Vecchi, A., Garlanda, C., Lampugnani, M. G., Resnati, M., Matteucci, C., Stoppacciaro, A., Schnurch, H., Risau, W., Ruco, L., and Mantovani, A. Monoclonal anti-bodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult embryonic endothelium. Eur. J. Cell. Biol., 63: 247-254, 1994.
23. Folkman, J., Watson, K., Ingher, D., and Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, (Lond.) 338: 59-61. 1989.
24. Bergers, G., Iavaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, (Washington DC) 284: 808-812, 1999.
25. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., and Fusenig, N. E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med., 3: 1222-1227, 1997.
26. Ruegg, C., Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P., and Lejeune, F. J. Evidence for the involvement of endothelial cell integrin vβ-3 in the disruption of the tumor vasculature induced by TNF and [FN-γ. Nat. Med., 4: 408-414, 1998.
27. Dias, S., Boyd, R., and Balkwill, F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int. J. Cancer, 78: 361-365, 1998.
28. Maini, A., Morse, P. D., Wang, C. Y., Jones, R. F., and Haas, G. P. New developments in the use of cytokines for cancer therapy. Anticancer Res., 17: 3803-3808, 1997.
29. Koblish, H. K., Hunter, C. A., Wysocka, M., Trinchieri, G., and Lee, W. M. Immune suppression by recombinant interleukin (rlL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of IL-12 vaccine adjuvant effect. J. Exp. Med., 188: 1603-1610, 1998.